Fig 1: GENT2 Meta-survival analysis and Kaplan–Meier Plotter survival analysis. (A) The meta-survival analysis for METTL8, HSPB3, and ERLIN2 based on the GENT2 database. (B) The survival analysis of METTL8, HSPB3, and ERLIN2 based on the Kaplan–Meier Plotter database.
Fig 2: Gene set enrichment analysis (GSEA) and experiment of METTL8. (A) The top diagram shows the enriched split lines of the three pathways, and the bottom diagram shows the genes for each pathway. (B) The circle shows three enrichment pathways and the significant genes that are involved in the enrichment process. The larger the circle for each gene, the greater the rating scale score. (C) The mRNA levels between normal control and si-METTL8 by METTL8 siRNA of SK-MES-1 cells. (D) The proliferation ability of si-METTL8 by METTL8 siRNA compared with the normal control by MTT analysis. (E) The effect of proliferation of METTL8 by EdU analysis between METTL8 siRNA and NC. (F) Cell cycle of si-METTL8 by METTL8 siRNA compared with the normal control by flow cytometry. (G) The level of PCNA, c-myc, and Cdc25c of METTL8 KD by shRNA compared with the normal control and vector group by WB.
Fig 3: The function and expression of METTL8 in vivo and patients. (A) NCI-H520 cells with the METTL8 shRNA lentivirus plasmid transfected or untransfected were injected into the subcutis of athymic BALB/c nude mice (4 weeks old). The xenografts were removed and measured at 70 days. (B) The tumor volume and weights of the xenografts. (C) Immunohistochemetry (IHC) staining was utilized to confirm the level of PCNA and Cdc25c in vivo. (D) IHC staining was utilized to confirm the level of METTL8 in tissues of normal lung, para-carcinoma, and LSCC. (E) The correlation analysis among METTL8, PCNA, myc, and Cdc25c in LSCC based on the TCGA database.
Supplier Page from Abcam for Anti-METTL8 antibody